Lipoprotein(a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH.
This prospective, randomized, controlled study compared the effects of recombinant human FSH (r-hFSH) and highly purified urinary FSH (u-hFSH HP) on lipoprotein(a) [Lp(a)] concentrations in women undergoing ovarian stimulation. Fifty infertile women were randomly allocated into two equally sized treatment groups (n = 25 per group). Thirty normal ovulation women were recruited as controls. The infertile women received u-hFSH or r-hFSH 150 IU/day starting on cycle day 2. From cycle day 6 the dose was adjusted according to ovarian response. Human chorionic gonadotrophin 10,000 IU was administered once there was at least one follicle > or =18 mm in diameter. The luteal phase was supported with progesterone 50 mg/day for at least 15 days. Repeated measurements of Lp(a) concentrations were performed during both stimulated and natural cycles. A significant increase in luteal phase Lp(a) concentrations was detected in the stimulated cycles, whereas no significant changes in serum Lp(a) concentrations were observed during natural cycles. There were no significant differences between the urinary and recombinant FSH effects on serum Lp(a). The luteal Lp(a) increase was transitory because after 1 month Lp(a) concentrations returned to baseline values if pregnancy failed to occur; in pregnant women persistent increased Lp(a) concentrations were found at the 8th week. The percentage changes in serum Lp(a) were positively correlated with the luteal progesterone increase (r = 0.40, P < 0.05), but not with follicular or luteal oestradiol increase. The women with low baseline Lp(a) (< or =5 mg/dl) had a greater increase of the Lp(a) concentrations at midluteal phase than women with baseline Lp(a) >5 mg/dl. In conclusion, the recombinant or urinary hFSH administration does not directly influence Lp(a) concentrations. The luteal Lp(a) increase in stimulated cycles is not related to gonadotrophin treatment per se, but appears to be related to the high luteal progesterone concentrations, physiologically or pharmacologically determined. Our results also suggest that the sensitivity to the progesterone changes could be related to apolipoprotein(a) phenotype.
UCO di Ginecologia e Ostetricia, Dipartimento di Scienze della Riproduzione e dello Sviluppo, Università di Trieste, Istituto per l'Infanzia Burlo Garofolo, I.R.C.C.S., Trieste, Italy. ricci@burlo.trieste.it
G
G
Ricci
G
G
Tamaro
R
R
Simeone
E
E
Giolo
G
G
Nucera
F
F
De Seta
S
S
Guaschino
D000328:Adult; D016022:Case-Control Studies; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000302:isolation & purification / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D017270:Lipoprotein(a) / Q000097:blood*; D008183:Luteal Phase / Q000378:metabolism; D008597:Menstrual Cycle / Q000097:blood* / Q000187:drug effects; D010053:Ovary / Q000187:drug effects*; D011247:Pregnancy; D011374:Progesterone / Q000378:metabolism / Q000627:therapeutic use; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D012016:Reference Values; D013997:Time Factors; D014556:Urine / Q000737:chemistry*
D006063:Chorionic Gonadotropin; D017270:Lipoprotein(a); D011994:Recombinant Proteins; D011374:Progesterone; D005640:Follicle Stimulating Hormone